PDCD1 and neoplasm: The CHECKMATE [8–10] series of trials have suggested that a specific threshold of “tumour mutational burden” (TMB) must be reached in order for PD-1 blockade to become effective, although this has not been adopted formally, due to a lack of association between TMB and response, although other similar markers such as clonal TMB have shown promise.